Literature DB >> 2184744

Porphyria and porphyrin metabolism.

J G Straka1, J M Rank, J R Bloomer.   

Abstract

Porphyrins, their reduced congeners (porphyrinogens), and their precursors are accumulated and excreted in excessive amounts in the porphyrias because of defects in the enzymes of heme biosynthesis. The nature of these defects is being defined using biochemical and molecular biological techniques. The principal clinical manifestations in the porphyrias, photocutaneous lesions and neurological dysfunction, are linked to the biochemical abnormalities, and appropriate therapeutic interventions have accordingly been developed. The exogenous administration of metalloporphyrins and porphyrin derivatives, unlike the harmful effects of porphyrins in the porphyrias, may be of use in some clinical conditions, such as the treatment of hyperbilirubinemic states and the detection and therapy of certain cancers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184744     DOI: 10.1146/annurev.me.41.020190.002325

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  11 in total

1.  Acute intermittent porphyria treated by testosterone implant.

Authors:  M W Savage; P Reed; S L Orrman-Rossiter; C Weinkove; D C Anderson
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

2.  Tetrapyrrole Metabolism in Arabidopsis thaliana.

Authors:  Ryouichi Tanaka; Koichi Kobayashi; Tatsuru Masuda
Journal:  Arabidopsis Book       Date:  2011-07-31

3.  A modified spectrophotometric assay for porphobilinogen deaminase: its application in the detection of both carriers and patients with acute intermittent porphyria.

Authors:  J Vázquez-Prado; F J Sánchez-Anzaldo; G J Ruiz-Argüelles; E Marín-López; E Lobato-Mendizábal
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Peripheral neuropathy in chronic occupational inorganic lead exposure: a clinical and electrophysiological study.

Authors:  O Rubens; I Logina; I Kravale; M Eglîte; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-08       Impact factor: 10.154

Review 5.  The little imitator--porphyria: a neuropsychiatric disorder.

Authors:  H L Crimlisk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

6.  Compartmentalization of the Edinburgh Human Metabolic Network.

Authors:  Tong Hao; Hong-Wu Ma; Xue-Ming Zhao; Igor Goryanin
Journal:  BMC Bioinformatics       Date:  2010-07-22       Impact factor: 3.169

7.  A porphyrin pathway impairment is responsible for the phenotype of a dominant disease lesion mimic mutant of maize.

Authors:  G Hu; N Yalpani; S P Briggs; G S Johal
Journal:  Plant Cell       Date:  1998-07       Impact factor: 11.277

8.  Acute intermittent porphyria associated with respiratory failure: a multidisciplinary approach.

Authors:  Mayra Gonçalves Menegueti; Alkmim-Teixeira Gil Cezar; Karin Aparecida Casarini; Kátia Simone Muniz Cordeiro; Anibal Basile-Filho; Olindo Assis Martins-Filho; Maria Auxiliadora-Martins
Journal:  Crit Care Res Pract       Date:  2011-05-11

9.  Phosphoprotein SAK1 is a regulator of acclimation to singlet oxygen in Chlamydomonas reinhardtii.

Authors:  Setsuko Wakao; Brian L Chin; Heidi K Ledford; Rachel M Dent; David Casero; Matteo Pellegrini; Sabeeha S Merchant; Krishna K Niyogi
Journal:  Elife       Date:  2014-05-23       Impact factor: 8.140

10.  Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases.

Authors:  Giacomo Canesin; Annalisa Di Ruscio; Mailin Li; Simone Ummarino; Andreas Hedblom; Reeham Choudhury; Agnieszka Krzyzanowska; Eva Csizmadia; Macarena Palominos; Anna Stiehm; Alexander Ebralidze; Shao-Yong Chen; Mahmoud A Bassal; Ping Zhao; Emanuela Tolosano; Laurence Hurley; Anders Bjartell; Daniel G Tenen; Barbara Wegiel
Journal:  Cell Rep       Date:  2020-09-22       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.